WebMar 28, 2024 · CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity … WebSep 16, 2024 · “The CyPath technology can be applied to many cancers in addition to lung cancers,” Zannes said, pointing, for example, to prostate and bladder cancers.
bioAffinity (BIAF) Reports Publication of Peer-Reviewed Paper on ...
WebSep 14, 2024 · CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2024 (SAN ANTONIO, TX) bioAffinity … WebThe CyPath ® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT). CyPath ® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding. The test … dylan mclean
BioAffinity Automated Flow Cytometry Test Detects …
WebJul 7, 2024 · CYPATH's laboratory aims to scan two million slides per year. So far, an estimated less than five percent of labs across Europe have enhanced their pathology … WebOct 14, 2024 · Reveles leads CyPath® Lung, a non-invasive and highly accurate test for lung cancer, as it enters the market OCTOBER 14, 2024 (SAN ANTONIO, TX) bioAffinity Technologies today announced that Xavier T. Reveles, MS, CG, has been promoted to Vice President of Operations. Reveles will be responsible for overseeing the … WebNov 17, 2024 · BioAffinity’s CyPath Lung uses flow cytometry to analyze the cells in a person’s sputum, or phlegm, to find cancer cells that have sloughed off a lung tumor during collection of the sample. To get a … dylan merritt obituary